Volanesorsen for treating familial chylomicronaemia syndrome
KEYWORDS: volanesorsen, committee, clinical, treatment, levels, patients, people, fcs, company, approach, model, risk, noted, erg, utility

considered academic in confidence by the company, so cannot be presented here. The committee was also aware that only 1 patient stopped treatment in the EAMS because of cancer recurrence. However, it questioned whether this would be seen in clinical practice because of the different dosing regimen (see section 3.1 and section 4.17). The ERG explained that the stopping rate at the licensed dose in clinical practice was currently unknown but was unlikely to be zero. 4.22 At consultation, the ERG clarified that, based on clinical expert opinion, it would expect a stopping rate of 10% per year and up to 20% continuing treatment in total. The committee understood that stopping treatment in trials was not only because of the stopping rules in the summary of product characteristics (see section 3.1). Stopping rates (including rate of dose pauses and missed doses) from the EAMS are commercial in confidence by the company, so cannot be presented here. However, the committee noted that the data suggested some people would stop treatment or pause doses in the trials and the EAMS, regardless of dosing regimen even after being on treatment for 2 or 3 years. Therefore, this trend seems to support some late
